TY - JOUR
T1 - A cross-sectional analysis of Zika virus infection in symptomatic and asymptomatic non-pregnant travellers: experience of a European reference center during the outbreak in the Americas
AU - Huits, Ralph
AU - Maniewski, Ula
AU - Van Den Bossche, Dorien
AU - Lotgering, Erica
AU - Tsoumanis, Achilleas
AU - Cnops, Lieselotte
AU - Jacobs, Jan
AU - Van Esbroeck, Marjan
AU - Bottieau, Emmanuel
N1 - NPP
PY - 2019
Y1 - 2019
N2 - BACKGROUND: Zika virus (ZIKV) infection a concern to travellers because of potential sexual transmission and adverse pregnancy outcomes.OBJECTIVE: To describe our experience in diagnosing ZIKV in travellers returning from endemic territories.METHOD: Travellers were evaluated for ZIKV at our clinic in a 12-month period during the outbreak, using ZIKV-specific RT-PCR and anti-ZIKV Immunoglobulin M/G ELISA when symptomatic, and ELISA only for asymptomatic travellers, preferably from 20 days after the last exposure. All positive ELISA results were subject to confirmation by Virus Neutralization Testing. We estimated post-test probabilities of ZIKV in asymptomatic travellers.RESULTS: Of 462 travellers, 227 reported symptoms and 235 did not. Asymptomatic travellers had similar baseline characteristics, but were younger (median age 31 vs. 33 years, p = 0.01) and had reproductive concerns more often (75.8% vs. 24.2%). ZIKV infection was confirmed in 49 cases: 46/227 (20.3%) were symptomatic and 3/235 (1.3%) asymptomatic. Rash (positive likelihood ratio (LRP) 5.6) and conjunctivitis (LRP 10.8) predicted ZIKV infection. The post-test probability of a negative ELISA-result at 20-25 days was below 0.1%.CONCLUSION: ZIKV infection was frequent in symptomatic, but not in asymptomatic travellers. We consider negative ELISA results at 20-25 days after exposure a safe strategy to rule out ZIKV infection. Testing for ZIKV-specific antibodies within this timeframe could be particularly valuable in the management of returning travellers who wish to conceive.
AB - BACKGROUND: Zika virus (ZIKV) infection a concern to travellers because of potential sexual transmission and adverse pregnancy outcomes.OBJECTIVE: To describe our experience in diagnosing ZIKV in travellers returning from endemic territories.METHOD: Travellers were evaluated for ZIKV at our clinic in a 12-month period during the outbreak, using ZIKV-specific RT-PCR and anti-ZIKV Immunoglobulin M/G ELISA when symptomatic, and ELISA only for asymptomatic travellers, preferably from 20 days after the last exposure. All positive ELISA results were subject to confirmation by Virus Neutralization Testing. We estimated post-test probabilities of ZIKV in asymptomatic travellers.RESULTS: Of 462 travellers, 227 reported symptoms and 235 did not. Asymptomatic travellers had similar baseline characteristics, but were younger (median age 31 vs. 33 years, p = 0.01) and had reproductive concerns more often (75.8% vs. 24.2%). ZIKV infection was confirmed in 49 cases: 46/227 (20.3%) were symptomatic and 3/235 (1.3%) asymptomatic. Rash (positive likelihood ratio (LRP) 5.6) and conjunctivitis (LRP 10.8) predicted ZIKV infection. The post-test probability of a negative ELISA-result at 20-25 days was below 0.1%.CONCLUSION: ZIKV infection was frequent in symptomatic, but not in asymptomatic travellers. We consider negative ELISA results at 20-25 days after exposure a safe strategy to rule out ZIKV infection. Testing for ZIKV-specific antibodies within this timeframe could be particularly valuable in the management of returning travellers who wish to conceive.
KW - Adult
KW - Americas/epidemiology
KW - Asymptomatic Infections/epidemiology
KW - Conjunctivitis/etiology
KW - Cross-Sectional Studies
KW - Disease Outbreaks/statistics & numerical data
KW - Enzyme-Linked Immunosorbent Assay
KW - Europe/epidemiology
KW - Exanthema/etiology
KW - Female
KW - Humans
KW - Immunoglobulin M/blood
KW - Male
KW - Middle Aged
KW - Pregnancy
KW - RNA, Viral
KW - Travel-Related Illness
KW - Zika Virus
KW - Zika Virus Infection/diagnosis
U2 - 10.1016/j.tmaid.2018.08.007
DO - 10.1016/j.tmaid.2018.08.007
M3 - A1: Web of Science-article
C2 - 30205195
VL - 27
SP - 107
EP - 114
JO - Travel Medicine and Infectious Disease
JF - Travel Medicine and Infectious Disease
SN - 1477-8939
ER -